GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Krebs Biochemicals & Industries Ltd-$

Krebs Biochemicals Amalgamation with Ipca Laboratories Approved

BOARD ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 26 Jun 2026, 01:19 PM IST  ·  BSE ID: d95b2012-d964-4dfb-9088-79dd77e36887
View Original BSE Filing (PDF)
💡
In Simple Terms
Krebs Biochemicals & Industries Ltd. will merge with Ipca Laboratories Ltd., pending approvals, with an April 1, 2026 target date.
🤖 AI Summary
  • Board approves amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd.
  • Scheme of Amalgamation is subject to necessary regulatory approvals under Companies Act and SEBI LODR
  • The appointed date for the Scheme of Amalgamation is April 1, 2026
  • Amalgamation is operative from the Effective Date upon receipt of all consents and approvals
🏢 How This Affects the Company
📈
Business Impact
The amalgamation will integrate Krebs Biochemicals' operations into Ipca Laboratories, potentially creating a larger entity with expanded market reach.
💰
Financial Impact
Specific financial impacts on balance sheets, debt, or margins are not detailed in this outcome filing; they will be assessed post-scheme finalization.
⚙️
Operational Impact
Operational integration plans and workforce adjustments are not specified in this announcement.
⚠️
Risk Impact
The primary risks relate to the successful completion of regulatory approvals and the integration process post-amalgamation.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders; they will be informed of further developments.
👤
Who Is Affected
All shareholders of Krebs Biochemicals & Industries Ltd. are affected by the proposed amalgamation.
🔍
Management Signal
The board's approval signifies management's intent to pursue strategic consolidation for potential growth and efficiency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Receipt of necessary approvals from Companies Act and SEBI
Announcement of the Effective Date of the Scheme of Amalgamation
Post-amalgamation integration updates from Ipca Laboratories
MEDIUM RISK Amalgamation is subject to multiple regulatory approvals, which may cause delays or alterations.
💡 Investor Takeaway
Krebs Biochemicals & Industries Ltd. board approved amalgamation with Ipca Laboratories Ltd. effective April 1, 2026, pending regulatory approvals.
❓ Frequently Asked Questions
What is the appointed date for the amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd.?
The appointed date for the Scheme of Amalgamation is April 1, 2026.
What approvals are required for the amalgamation of Krebs Biochemicals & Industries Ltd.?
The amalgamation is subject to necessary approvals under the relevant provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
When will the amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. become effective?
The amalgamation shall be operative from the Effective Date upon receipt of all consents and approvals as defined in the Scheme.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.